Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Insulet (PODD)
NASDAQ:PODD
Insulet (PODD) Stock Price & Analysis
685 Followers
PODD Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$125.82 - $320.27
Previous Close$180.56
Volume480.26K
Average Volume (3M)971.95K
Market Cap
$12.96B
Enterprise Value$13.38B
Total Cash (Recent Filing)$685.40M
Total Debt (Recent Filing)$1.42B
Price to Earnings (P/E)54.6
Beta1.06
Next Earnings
Aug 07, 2024EPS Estimate
$0.56Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.31
Shares Outstanding70,039,511
10 Day Avg. Volume1,398,531
30 Day Avg. Volume971,947
Standard Deviation0.13
R-Squared0.17
Alpha0.00890
Financial Highlights & Ratios
Price to Book (P/B)18.84
Price to Sales (P/S)9.69
Price to Cash Flow (P/CF)34.40
P/FCF Ratio41.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue8.59
Enterprise Value/Gross Profit16.61
Enterprise Value/Ebitda98.03
Forecast
1Y Price Target
$232.07Price Target Upside25.43% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
Insulet News
Bulls Say, Bears Say
Bulls Say
Financial PerformanceInsulet's first quarter results showed robust global revenue surpassing projections, with strong execution reflected in improved margins and an upward revision of full year guidance.
Guidance And Analyst SentimentAnalysts are increasingly optimistic about Insulet's future performance, bolstered by raised guidance for U.S. and international revenue growth and the potential impact of the expanding Type 2 diabetes market.
Product And Market DevelopmentAnticipated new product releases and label expansions, along with the innovative Omnipod 5 insulin pump, position Insulet for significant growth within the lucrative insulin pump market.
Bears Say
Financial GuidanceQ1 revenue guidance is below consensus, which may reflect a negative market perception and impact investor confidence.
Market ShareU.S. competitive converts likely fell, indicating potential challenges in market share growth.
Revenue And Profitability2024 EPS estimate lowered due to an increased tax rate, which may impact net profitability.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
PODD FAQ
What was Insulet’s price range in the past 12 months?
Insulet lowest stock price was $125.82 and its highest was $320.27 in the past 12 months.
What is Insulet’s market cap?
Currently, no data Available
When is Insulet’s upcoming earnings report date?
Insulet’s upcoming earnings report date is Aug 07, 2024 which is in 83 days.
How were Insulet’s earnings last quarter?
Insulet released its earnings results on May 09, 2024. The company reported $0.73 earnings per share for the quarter, beating the consensus estimate of $0.401 by $0.329.
Is Insulet overvalued?
According to Wall Street analysts Insulet’s price is currently Undervalued.
Does Insulet pay dividends?
Insulet does not currently pay dividends.
What is Insulet’s EPS estimate?
Insulet’s EPS estimate is $0.56.
How many shares outstanding does Insulet have?
Insulet has 70,039,510 shares outstanding.
What happened to Insulet’s price movement after its last earnings report?
Insulet reported an EPS of $0.73 in its last earnings report, beating expectations of $0.401. Following the earnings report the stock price went down -6.551%.
Which hedge fund is a major shareholder of Insulet?
Among the largest hedge funds holding Insulet’s share is D1 Capital Partners LP. It holds Insulet’s shares valued at 172M.
---
Insulet Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$232.07 (25.43% Upside)
$232.07 (25.43% Upside)
Blogger Sentiment
Bullish
PODD Sentiment 75%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 90.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.4%
Last 30 Days ▲ 0.6%
Last 30 Days ▲ 0.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-43.71%
12-Months-Change
Fundamentals
Return on Equity
36.18%
Trailing 12-Months
Asset Growth
14.63%
Trailing 12-Months
Company Description
Insulet
Insulet Corp. is a medical device company. The firm engages in the development, manufacture and marketing of an insulin infusion system for people with insulin-dependent diabetes. It specializes in diabetes supplies, including the OmniPod System as well as other diabetes related products and supplies such as blood glucose testing supplies, traditional insulin pumps, pump supplies, and pharmaceuticals. The company was founded by John L. Brooks III and John T. Garibotto in July 2000 and is headquartered in Acton, MA.
---
PODD Company Deck
---
PODD Earnings Call
Q1 2024
0:00 / 0:00
---
PODD Revenue Breakdown
73.71% U.S. Omnipod
24.16% International Omnipod
2.12% Drug Delivery
---
PODD Stock 12 Month Forecast
Average Price Target
$232.07
▲(25.43% Upside)
Technical Analysis
Best Analysts Covering PODD
1 Year
1 Year Success Rate
18/26 ratings generated profit
1 Year Average Return
+16.35%
reiterated a buy rating 7 days ago
Copying Jayson Bedford's trades and holding each position for 1 Year would result in 69.23% of your transactions generating a profit, with an average return of +16.35% per trade.
---